05:41 PM EDT, 06/03/2025 (MT Newswires) -- AnaptysBio ( ANAB ) late Tuesday reported updated interim results from its ongoing phase 2b trial of rosnilimab in patients with moderate-to-severe rheumatoid arthritis, showing that most participants improved after three months of treatment, with many maintaining those gains for at least two months after stopping therapy.

The company said the durability of response supports the potential for extended maintenance dosing intervals, including every eight weeks, based on data showing continued benefit even after treatment discontinuation.

Rosnilimab also demonstrated a favorable safety and tolerability profile, particularly compared to standard biologic therapies and Janus kinase inhibitors, with no treatment-related serious adverse events or safety signals reported.

The company said it expects to report full trial results by the end of 2025.

AnaptysBio ( ANAB ) shares were up more than 6% in after-hours activity.